Freeline announces supply agreement for haemophilia B program
LONDON, Sept. 23, 2020 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical stage, […]
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
CAMBRIDGE, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed […]
36Kr Holdings Inc. Announces Strategic Collaboration with Youku to Enhance Content Commercialization
BEIJING, Sept. 23, 2020 (GLOBE NEWSWIRE) — 36Kr Holdings Inc. (“36Kr” or the “Company”) (NASDAQ: KRKR), a prominent brand and […]
First Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory Gout
STOCKHOLM, Sweden and WATERTOWN, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta […]
Hamilton Lane Names Paul Yett as Director of ESG & Sustainability
BALA CYNWYD, Pa., Sept. 23, 2020 (GLOBE NEWSWIRE) — Leading private markets asset management firm Hamilton Lane (NASDAQ: HLNE) today […]
TSX News -
Troilus Launches New 20,000 Metre Drill Program Following Release of Positive Preliminary Economic Assessment
TORONTO, Sept. 23, 2020 (GLOBE NEWSWIRE) — Troilus Gold Corp. (TSX: TLG; OTCQB: CHXMF) (“Troilus” or the “Company”) has initiated […]
NexTech AR Record $900,000 Bookings For Video Conferencing and Virtual Events Platform ‘InfernoAR’
VANCOUVER, British Columbia, Sept. 23, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), an […]
Worthington Reports First Quarter Fiscal 2021 Results
COLUMBUS, Ohio, Sept. 23, 2020 (GLOBE NEWSWIRE) — Worthington Industries, Inc. (NYSE: WOR) today reported net sales of $702.9 million […]
MediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2 in Mice using BC-PIV Vector Technology
LA JOLLA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market […]
Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057
First orally available integrin inhibitor from MInT Platform to enter the clinicMORF-057, inhibitor of α4β7integrin, in development to treat inflammatory […]
